Last reviewed · How we verify
NCT05719012
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19
Withdrawn
Phase 2
Last updated 21 November 2023
What this trial tests
Phase 2 trial testing UC-MSCs in Long COVID-19. Withdrawn.
Timeline
1 April 2023
Primary endpoint
1 December 2023
1 December 2023
30 March 2024
Quick facts
| Lead sponsor | Shanghai East Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Start date | 1 April 2023 |
| Primary completion | 1 December 2023 |
| Estimated completion | 30 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- UC-MSCs — full drug profile →
Conditions studied
- Long COVID-19 — all drugs for Long COVID-19 →
Sponsor
Shanghai East Hospital
Who can join
Adults 18 to 80, any sex, with Long COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic utility of human umbilical cord-derived mesenchymal stem cells-based approaches in pulmonary diseases: Recent advancements and prospects.
Meng M, Zhang WW, Chen SF, Wang DR, et al · · 2024 · cited 10× · PMID 38455096 · DOI 10.4252/wjsc.v16.i2.70 -
Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment.
Fang Y, Lao P, Tang L, Chen J, et al · · 2023 · cited 8× · PMID 37395459 · DOI 10.1177/09636897231184611 -
Immune-Cell-Based Therapy for COVID-19: Current Status.
Wang Y, Liang Q, Chen F, Zheng J, et al · · 2023 · cited 3× · PMID 38005826 · DOI 10.3390/v15112148 -
Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.
Carbone-Schellman J, Fontecilla-Escobar J, Sales-Salinas N, Chaparro-Pico WF, et al · · 2025 · cited 1× · PMID 41235241 · DOI 10.3389/fimmu.2025.1677433 -
Modular mastery of inflammation: umbilical cord mesenchymal stem cells as a therapeutic frontier.
Yin L, Sun CY, Chen GL, Xiang Z, et al · · 2025 · PMID 41488628 · DOI 10.3389/fimmu.2025.1721947
Verify or expand the search:
- PubMed search for NCT05719012
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of UC-MSCs
Trials testing the same drug.
- NCT06463847 — Phase I Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis · Phase 1 · recruiting
- NCT05224960 — Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) · Phase 2 · recruiting
- NCT05279768 — Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. · Phase 1, PHASE2 · completed
- NCT05121870 — Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis · Phase 2 · unknown
- NCT05507762 — Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage) · Phase 1, PHASE2 · unknown
Other recruiting trials for Long COVID-19
Currently open trials in the same condition.
- NCT06960928 — Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 · Phase 3 · recruiting
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06404099 — RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) · Phase 2 · active not recruiting
- NCT06404112 — RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) · Phase 2 · active not recruiting
- NCT07005947 — Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project · active not recruiting
Other Shanghai East Hospital trials
Trials by the same sponsor.
- NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
- NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
- NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
- NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
- NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05719012 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
- Last refreshed: 21 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05719012.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing